Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Assets (2016 - 2025)

Ironwood Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $274.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 50.34% year-over-year to $274.2 million; the TTM value through Dec 2025 reached $274.2 million, up 50.34%, while the annual FY2025 figure was $274.2 million, 50.34% up from the prior year.
  • Current Assets for Q4 2025 was $274.2 million at Ironwood Pharmaceuticals, roughly flat from $273.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $866.4 million in Q1 2023 and bottomed at $160.6 million in Q1 2025.
  • The 5-year median for Current Assets is $295.9 million (2023), against an average of $436.3 million.
  • The largest annual shift saw Current Assets soared 65.73% in 2021 before it plummeted 75.97% in 2024.
  • A 5-year view of Current Assets shows it stood at $745.2 million in 2021, then grew by 4.75% to $780.6 million in 2022, then crashed by 70.12% to $233.3 million in 2023, then decreased by 21.83% to $182.4 million in 2024, then surged by 50.34% to $274.2 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Current Assets are $274.2 million (Q4 2025), $273.8 million (Q3 2025), and $191.8 million (Q2 2025).